Sarah Cannon September 03, 2015

NASHVILLE, TENN., September 3, 2015 – Sarah Cannon Research Institute (SCRI) announced today that the International Association for the Study of Lung Cancer (IASLC) has selected Sarah Cannon investigators to present in 11 oral presentations, 7 posters, an education session and a symposium at the 16th World Conference on Lung Cancer (WCLC) in Denver, Colo., September 6-9. The WCLC is the world’s largest meeting for lung cancer experts to review research data related to lung cancer and other thoracic malignancies.

Through the more than 20 presentations, Sarah Cannon research leaders will highlight studies on immunotherapies and molecular targeted agents for lung cancer. Sarah Cannon investigators will also provide insight in discussion sessions and a CME symposium held during the conference.

“Lung cancer takes more lives than any other type of cancer every year. With the emergence of immunotherapies as well as targeted therapies tailored to genetic mutations, we are observing a promising shift in how we can more effectively treat this disease,” said Chief Medical Officer and Executive Director, Sarah Cannon’s Drug Development Program, Howard A. Burris III, MD. “Our participation in the WCLC annual meeting demonstrates Sarah Cannon’s leadership in investigating novel agents that are designed to improve outcomes for patients.”

Sarah Cannon investigators presenting noteworthy studies at the annual meeting include:

  • David R. Spigel, MD, Director, Lung Cancer Research Program at Sarah Cannon, will discuss the progress of personalized treatment for targeting ALK, ROS-1, BRAF, RET, and EGFR mutations in lung cancer in an education session, in addition to an oral presentation on a Phase II trial of pictilisib with chemotherapy in first-line squamous non-small cell lung cancer (NSCLC).
  • Melissa Johnson, MD, Associate Director, Lung Cancer Research Program at Sarah Cannon, will present a poster on the results from a study comparing Next-Generation Sequencing (NGS) platforms in patients with thoracic tumors, highlighting the differences in tumor tissue vs. circulating cell-free DNA from blood. Dr. Johnson will also discuss the severity of adverse events in immunotherapy vs. chemotherapy in a sponsored symposium on immuno-oncology in advanced NSCLC.
  • Todd M. Bauer, MD, Associate Director, Drug Development at Sarah Cannon, will provide an update on the clinical activity and safety results of the first-in-human trial of ALK/ROS1 TK inhibitor PF-06463922 in advanced NSCLC in an oral presentation at the conference.

Additional presentations at the conference include work from the following Sarah Cannon investigators: Howard A. Burris III, MD, Johanna C. Bendell, MD, Maen A. Hussein, MD, Michael J. McCleod, DO, Manish R. Patel, MD, Dana Thompson, MD, and David M. Waterhouse, MD.

For full details on Sarah Cannon’s presence at the conference, visit sarahcannon.com/campaigns/world-lung.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is the research arm of HCA’s global cancer institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world’s leading clinical research organizations conducting community-based clinical trials in oncology, cardiology and orthopedics through affiliations with a network of more than 1,000 physicians across the United States and United Kingdom. SCRI has led more than 170 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in nearly 80 percent of approved cancer therapies in the last 10 years. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), SCRI Development Innovations. For more information, visit sarahcannon.com.

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes nearly 4,000 lung cancer specialists in 80 countries. For more information, visit www.iaslc.org.

tags: home , sarah cannon